Onco Wiki / Regimen

Pembrolizumab monotherapy (MSI-H mCRC 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-PEMBROLIZUMAB
IDREG-PEMBROLIZUMAB-MSI-MONO
TypeRegimen
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-COLON-2024 SRC-KEYNOTE-177-ANDRE-2020 SRC-NCCN-COLON-2025

Notes

KEYNOTE-177: PFS 16.5 vs 8.2 mo over FOLFOX+bev in MSI-H mCRC 1L; OS endpoint diluted by crossover but persistent ORR + duration benefit. Single-agent (no chemo backbone needed for MSI-H — explosive ORR ~50%). irAE awareness critical — hyperprogression rare but reported in MSI-L patients incorrectly treated.

Used By

Contraindications

Handbook Chapters

Indication